TNFSF15 modulates neovascularization and inflammation

Cancer Microenvironment

Volumn 5, Issue 3, 2012, Pages 237-247

  Zhang, Zhisong ^a   Li, Lu Yuan ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

Cytokine; Neovascularization; TL1A; TNFSF15; VEGI

Indexed keywords

DEATH RECEPTOR 3; DECOY RECEPTOR 3; RECOMBINANT CYTOKINE; RECOMBINANT TNFSF15; RECOMBINANT VEGI 192; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR; VEGI 174; VEGI 192;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CELL MATURATION; COLON CANCER; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; ENDOTHELIAL PROGENITOR CELL; GENE MAPPING; GROWTH INHIBITION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; LEWIS CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TERTIARY STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SOLID MALIGNANT NEOPLASM; WOUND HEALING;

EID: 84864107643     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-012-0117-8     Document Type: Article

References (106)

1. Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11:372-377
2. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45-65
3. Zielinski CC et al (1990) Impaired production of tumor necrosis factor in breast cancer. Cancer 66:1944-1948
4. Mallmann P, Diedrich K, Mallmann R, Koenig UD, Krebs D (1991) Determination of TNF alpha, interferon alpha, interleukin 2 and reactivity in the leucocyte migration inhibition test in breast cancer patients. Anticancer Res 11:1509-1515
5. Husby G, Williams RC Jr (1988) Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1:363-371
6. Buchan G et al (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 73:449-455
7. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516-518
8. Piguet PF, Grau GE, Hauser C, Vassalli P (1991) Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J Exp Med 173:673-679
9. Satoh J et al (1990) Inhibition of type 1 diabetes in BB rats with recombinant human tumor necrosis factor-alpha. J Immunol 145:1395-1399
10. Held W, MacDonald HR, Weissman IL, Hess MW, Mueller C (1990) Genes encoding tumor necrosis factor alpha and granzyme A are expressed during development of autoimmune diabetes. Proc Natl Acad Sci U S A 87:2239-2243
11. Rus HG, Niculescu F, Vlaicu R (1991) Tumor necrosis factoralpha in human arterial wall with atherosclerosis. Atherosclerosis 89:247-254
12. Lissoni P et al (1992) Enhanced secretion of tumour necrosis factor in patients with myocardial infarction. Eur J Med 1:277-280
13. Piguet PF, Grau GE, Allet B, Vassalli P (1987) Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166:1280-1289
14. Lahdevirta J et al (1988) Elevated levels of circulating cachectin/ tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 85:285-291
15. Gaur U, Aggarwal BB (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol 66:1403-1408
16. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745-756
17. Zhai Yet al (1999) VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13:181-189
18. Yue TL et al (1999) TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 274:1479-1486
19. Migone TS et al (2002) TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16:479-492
20. Yu J et al (2001) Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. Circ Res 89:1161-1167
21. Zhai Y et al (1999) Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82:131-136
22. Kim MYet al (2006) Neonatal and adult CD4+ CD3-cells share similar gene expression profile, and neonatal cells up-regulate OX40 ligand in response to TL1A (TNFSF15). J Immunol 177:3074-3081
23. Papadakis KA et al (2004) TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 172:7002-7007
24. Papadakis KA et al (2005) Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol 174:4985-4990
25. Tian F et al (2007) The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol 179:3742-3751
26. Ardavin C, Amigorena S, Reis e Sousa C (2004) Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20:17-23
27. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
28. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475-480
29. Tan KB et al (1997) Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204:35-46
30. Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27:19-26
31. Takimoto T, Takahashi K, Sato K, Akiba Y (2005) Molecular cloning and functional characterizations of chicken TL1A. Dev Comp Immunol 29:895-905
32. Chew LJ et al (2002) A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 16:742-744
33. Hou W, Medynski D, Wu S, Lin X, Li LY (2005) VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res 11:5595-5602
34. Jones GW et al (2011) Naive and activated T cells display differential responsiveness to TL1A that affects Th17 generation, maintenance, and proliferation. FASEB J 25:409-419
35. Qin T (2011) Upregulation of DR3 expression in CD4(+) T cells promotes secretion of IL-17 in experimental autoimmune uveitis. Mol Vis 17:3486-3493
36. Cohavy O, Shih DQ, Doherty TM, Ware CF, Targan SR (2011) Cd161 Defines Effector T Cells That Express Light and Respond to Tl1a-Dr3 Signaling. Eur J Microbiol Immunol (Bp) 1:70-79
37. Haritunians T et al (2010) Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 16:1830-1840
38. Chen X et al (2010) Approaches to efficient production of recombinant angiogenesis inhibitor rhVEGI-192 and characterization of its structure and antiangiogenic function. Protein Sci 19:449-457
39. Yang CR et al (2004) Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 64:1122-1129
40. Jin T, Guo F, Kim S, Howard A, Zhang YZ (2007) X-ray crystal structure of TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun 364:1-6
41. Zhan C et al (2009) Biochemical and structural characterization of the human TL1A ectodomain. Biochemistry 48:7636-7645
42. Mongkolsapaya J et al (1999) Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 6:1048-1053
43. Barrett R et al (2012) Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis. Am J Pathol 180:636-649
44. Hayashi S et al (2007) Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 56:1067-1075
45. Funke B et al (2009) Functional characterisation of decoy receptor 3 in Crohn’s disease. Gut 58:483-491
46. Zhang J et al (2001) Modulation of T-cell responses to alloantigens by TR6/DcR3. J Clin Invest 107:1459-1468
47. Young HA, Tovey MG (2006) TL1A: a mediator of gut inflammation. Proc Natl Acad Sci U S A 103:8303-8304
48. Deng W et al (2012) Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization. Angiogenesis 15:71-85
49. Kang YJ et al (2005) Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine 29:229-235
50. Jang SI et al (2011) Distinct immunoregulatory properties of macrophage migration inhibitory factors encoded by Eimeria parasites and their chicken host. Vaccine 29:8998-9004
51. Sagsoz H, Saruhan BG (2011) The expression of vascular endothelial growth factor and its receptors (flt1/fms, flk1/KDR, flt4) and vascular endothelial growth inhibitor in the bovine uterus during the sexual cycle and their correlation with serum sex steroids. Theriogenology 75:1720-1734
52. Zhou J et al (2011) LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene 30:1892-1900
53. Lambert C et al (2012) Characterization of synovial angiogenesis in osteoarthritis patients and its modulation by chondroitin sulfate. Arthritis Res Ther 14:R58
54. Saruta M et al (2009) TLR8-mediated activation of human monocytes inhibits TL1A expression. Eur J Immunol 39:2195-2202
55. Safaya S et al (2009) Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: differential expression patterns in pulmonary artery and microvascular endothelial cells. Cytokine 46:72-78
56. Xiao Q et al (2005) Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. Biochem J 388:913-920
57. Endo K et al (2010) Involvement of NF-kappa B pathway in TL1A gene expression induced by lipopolysaccharide. Cytokine 49:215-220
58. Haridas V et al (1999) VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18:6496-6504
59. Conway KP, Price P, Harding KG, Jiang WG (2007) The role of vascular endothelial growth inhibitor in wound healing. Int Wound J 4:55-64
60. Pan X et al (2004) Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol 10:1409-1414
61. Tian F et al (2009) Inhibition of endothelial progenitor cell differentiation by VEGI. Blood 113:5352-5360
62. Liang PH et al (2011) Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis 14:61-68
63. Al-Lamki RS et al (2012) DR3 signaling protects against cisplatin nephrotoxicity mediated by tumor necrosis factor. Am J Pathol 180:1454-1464
64. Wu J et al (2012) Dual Function of RGD-Modified VEGI-192 for Breast Cancer Treatment. Bioconjug Chem 23:796-804
65. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571
66. Meyer A, Auernheimer J, Modlinger A, Kessler H (2006) Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des 12:2723-2747
67. Parr C, Gan CH, Watkins G, Jiang WG (2006) Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9:73-81
68. Zhang N, Sanders AJ, Ye L, Kynaston HG, Jiang WG (2010) Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res 30:87-95
69. Heidemann SC et al (2010) TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets. J Clin Immunol 30:531-538
70. Pobezinskaya YL, Choksi S, Morgan MJ, Cao X, Liu ZG (2011) The adaptor protein TRADD is essential for TNF-like ligand 1A/ death receptor 3 signaling. J Immunol 186:5212-5216
71. Prehn JL et al (2007) The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol 178:4033-4038
72. Blach-Olszewska Z (2005) Innate immunity: cells, receptors, and signaling pathways. Arch Immunol Ther Exp (Warsz) 53:245-253
73. Shih DQ et al (2009) Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells. Eur J Immunol 39:3239-3250
74. Bamias G et al (2003) Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 171:4868-4874
75. Latiano A et al (2011) Investigation of multiple susceptibility loci for inflammatory bowel disease in an Italian cohort of patients. PLoS One 6:e22688
76. Peter I et al (2011) Evaluation of 22 genetic variants with Crohn’s disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet 12:63
77. Nakagome S et al (2010) Population-specific susceptibility to Crohn’s disease and ulcerative colitis; dominant and recessive relative risks in the Japanese population. Ann Hum Genet 74:126-136
78. Bamias G et al (2006) Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci U S A 103:8441-8446
79. Meylan F et al (2011) The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol 4:172-185
80. Taraban VY et al (2011) Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol 4:186-196
81. Shih DQ et al (2011) Constitutive TL1A (TNFSF15) expression on lymphoid or myeloid cells leads to mild intestinal inflammation and fibrosis. PLoS One 6:e16090
82. Cassatella MA et al (2007) Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol 178:7325-7333
83. Al-Lamki RS et al (2008) TL1A Both Promotes and Protects from Renal Inflammation and Injury. J Am Soc Nephrol
84. Bamias G et al (2011) Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions. Exp Dermatol 20:725-731
85. Fang L, Adkins B, Deyev V & Podack ER (2008) Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med
86. Pappu BP et al (2008) TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med
87. Bossen C et al (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281:13964-13971
88. Chinnaiyan AM et al (1996) Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274:990-992
89. Kitson J et al (1996) A death-domain-containing receptor that mediates apoptosis. Nature 384:372-375
90. Marsters SA et al (1996) Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol 6:1669-1676
91. Biener-Ramanujan E, Gonsky R, Ko B, Targan SR (2010) Functional signaling of membrane-bound TL1A induces IFN-gamma expression. FEBS Lett 584:2376-2380
92. Wen L, Zhuang L, Luo X, Wei P (2003) TL1A-induced NFkappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem 278:39251-39258
93. Bodmer JL et al (1997) TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity 6:79-88
94. Screaton GR et al (1997) LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci U S A 94:4615-4619
95. Takahama Y et al (2002) The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5:61-68
96. Roth W et al (2001) Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res 61:2759-2765
97. Ohshima K et al (2000) Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett 160:89-97
98. Bai C et al (2000) Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A 97:1230-1235
99. Pitti RM et al (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703
100. Bamias G et al (2010) High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 137:242-249
101. Hayashi S, Miura Y, Tateishi K, Takahashi M, Kurosaka M (2010) Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis. Mod Rheumatol 20:63-68
102. Wu SF et al (2004) Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J Leukoc Biol 75:293-306
103. Hsu TL et al (2002) Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J Immunol 168:4846-4853
104. Yang CR, Hsieh SL, Ho FM, Lin WW (2005) Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 174:1647-1656
105. Takahashi M et al (2011) DcR3-TL1A signalling inhibits cytokine-induced proliferation of rheumatoid synovial fibroblasts. Int J Mol Med 28:423-427
106. Hayashi S et al (2011) DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis. Osteoarthr Cartil 19:903-910